• Profile
Close

Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities

European Urology Aug 18, 2019

Lu-Yao G, Nikita N, Keith SW, et al. - Via a population-based retrospective study, researchers evaluated the short-term outcomes of abiraterone acetate (AA) and enzalutamide (ENZ) in patients with pre-existing cardiovascular disease (CVD). At least one pre-existing CVD was seen in 67% of eligible participants (2,845 on AA and 1,031 on ENZ). Having one to two pre-existing CVDs was related to 16% higher 6-month mortality; the risk was higher among those having three or more CVDs vs those without pre-existing CVDs. Elderly prostate cancer individuals with pre-existing CVDs encountered greater short-term mortality than comparable individuals without CVDs, following treatment with AA or ENZ. Mortality correlated with CVDs was not impacted on whether they received AA vs ENZ.

Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay